Drug testing plays a valuable role in the initial assessment and ongoing adherence monitoring in patients prescribed chronic opioid therapy and is recommended in multiple guidelines.
Testing is available for many medications utilized in the treatment of pain so that clinicians can customize their testing order to the medications and substances most appropriate for monitoring. Testing can be expanded or reduced according to the patient’s risk of adverse outcomes or substance misuse.
Contact us for more information on our complete flexible test menu.
Care for your patients with objective data regarding medication and substance use.
Knowing what medications have recently been ingested helps with prescribing decisions and patient education.
Results can help build a stronger treatment relationship and encourage healthy behaviors.11. Guidelines for the chronic use of opioid analgesics. Federation of State Medical Boards (FSMB) website. http://www.fsmb.org/globalassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf.
Merina Wijaya MacCabe, MSW
Princeton Pain and Spine Institute
BioDetect testing assists providers in identification of urine substitution with a non-biologic specimen, including things like synthetic urine and is included in testing on all urine specimens.
InterACT Rx testing, when used alongside definitive testing to assess prescription and non-prescription substance use, can improve care decisions through objective detection of ingested substances capable of contributing to drug-drug interactions and adverse drug events (ADEs).
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.
BioDetect testing assists providers in identification of urine substitution with a non-biologic specimen, including things like synthetic urine and is included in testing on all urine specimens.
InterACT Rx testing, when used alongside definitive testing to assess prescription and non-prescription substance use, can improve care decisions through objective detection of ingested substances capable of contributing to drug-drug interactions and adverse drug events (ADEs).
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.